Swiss National Bank Acquires New Holdings in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)

Share on StockTwits

Swiss National Bank purchased a new position in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 172,100 shares of the biopharmaceutical company’s stock, valued at approximately $661,000.

Several other large investors also recently bought and sold shares of CPRX. Gables Capital Management Inc. lifted its position in Catalyst Pharmaceuticals by 1.3% during the second quarter. Gables Capital Management Inc. now owns 486,064 shares of the biopharmaceutical company’s stock valued at $1,869,000 after purchasing an additional 6,300 shares during the period. Lido Advisors LLC grew its stake in Catalyst Pharmaceuticals by 11.8% during the 1st quarter. Lido Advisors LLC now owns 126,403 shares of the biopharmaceutical company’s stock valued at $644,000 after acquiring an additional 13,380 shares in the last quarter. Biltmore Capital Advisors LLC acquired a new position in Catalyst Pharmaceuticals in the 1st quarter valued at about $79,000. BNP Paribas Arbitrage SA acquired a new position in Catalyst Pharmaceuticals in the 1st quarter valued at about $102,000. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 122.4% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 94,960 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 52,260 shares during the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.

A number of research analysts recently commented on CPRX shares. SunTrust Banks reaffirmed a “buy” rating and issued a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 8th. Cantor Fitzgerald raised their target price on shares of Catalyst Pharmaceuticals from $10.00 to $12.00 in a report on Thursday, August 8th. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Wednesday, July 31st. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $8.54.

CPRX stock traded up $0.50 during midday trading on Friday, hitting $6.64. 1,915,745 shares of the company traded hands, compared to its average volume of 1,809,294. Catalyst Pharmaceuticals Inc has a twelve month low of $1.85 and a twelve month high of $7.67. The company has a quick ratio of 5.07, a current ratio of 5.09 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $712.27 million, a price-to-earnings ratio of -20.11 and a beta of 2.38. The business has a 50 day simple moving average of $5.65 and a 200-day simple moving average of $4.48.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. The company had revenue of $28.84 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the prior year, the company earned ($0.06) earnings per share. The business’s revenue was up 2883900.0% compared to the same quarter last year. Equities research analysts forecast that Catalyst Pharmaceuticals Inc will post 0.34 EPS for the current year.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Story: Most Active Stocks

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.